NGM vs. VTGN, KNTE, SYRS, PRQR, ASMB, VTVT, BYSI, IMMP, AVRO, and BLRX
Should you be buying NGM Biopharmaceuticals stock or one of its competitors? The main competitors of NGM Biopharmaceuticals include Vistagen Therapeutics (VTGN), Kinnate Biopharma (KNTE), Syros Pharmaceuticals (SYRS), ProQR Therapeutics (PRQR), Assembly Biosciences (ASMB), vTv Therapeutics (VTVT), BeyondSpring (BYSI), Immutep (IMMP), AVROBIO (AVRO), and BioLineRx (BLRX). These companies are all part of the "biotechnology" industry.
NGM Biopharmaceuticals (NASDAQ:NGM) and Vistagen Therapeutics (NASDAQ:VTGN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, community ranking, earnings, media sentiment, dividends, risk and analyst recommendations.
Vistagen Therapeutics received 249 more outperform votes than NGM Biopharmaceuticals when rated by MarketBeat users. Likewise, 72.24% of users gave Vistagen Therapeutics an outperform vote while only 60.38% of users gave NGM Biopharmaceuticals an outperform vote.
75.7% of NGM Biopharmaceuticals shares are owned by institutional investors. Comparatively, 78.4% of Vistagen Therapeutics shares are owned by institutional investors. 35.9% of NGM Biopharmaceuticals shares are owned by company insiders. Comparatively, 1.0% of Vistagen Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
In the previous week, Vistagen Therapeutics had 3 more articles in the media than NGM Biopharmaceuticals. MarketBeat recorded 3 mentions for Vistagen Therapeutics and 0 mentions for NGM Biopharmaceuticals. Vistagen Therapeutics' average media sentiment score of 0.35 beat NGM Biopharmaceuticals' score of 0.00 indicating that Vistagen Therapeutics is being referred to more favorably in the news media.
Vistagen Therapeutics has lower revenue, but higher earnings than NGM Biopharmaceuticals.
NGM Biopharmaceuticals currently has a consensus target price of $3.68, indicating a potential upside of 139.18%. Vistagen Therapeutics has a consensus target price of $19.00, indicating a potential upside of 300.00%. Given Vistagen Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Vistagen Therapeutics is more favorable than NGM Biopharmaceuticals.
Vistagen Therapeutics has a net margin of -3,073.51% compared to NGM Biopharmaceuticals' net margin of -3,223.34%. Vistagen Therapeutics' return on equity of -72.10% beat NGM Biopharmaceuticals' return on equity.
NGM Biopharmaceuticals has a beta of 1.27, meaning that its share price is 27% more volatile than the S&P 500. Comparatively, Vistagen Therapeutics has a beta of 0.77, meaning that its share price is 23% less volatile than the S&P 500.
Summary
Vistagen Therapeutics beats NGM Biopharmaceuticals on 13 of the 16 factors compared between the two stocks.
Get NGM Biopharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for NGM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NGM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NGM Biopharmaceuticals Competitors List
Related Companies and Tools
